Relay Therapeutics, Inc.
$16.4
▲
16.43%
2026-04-21 09:10:00
www.relaytx.com
NGM: RLAY
Explore Relay Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3 B
Current Price
$16.4
52W High / Low
$17.32 / $2.53
Stock P/E
—
Book Value
$3.26
Dividend Yield
—
ROCE
-50.82%
ROE
-41.12%
Face Value
—
EPS
$-1.61
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
192
Beta
1.58
Debt / Equity
5.72
Current Ratio
22.61
Quick Ratio
22.61
Forward P/E
-9.65
Price / Sales
173.9
Enterprise Value
$2.15 B
EV / EBITDA
-7.18
EV / Revenue
139.9
Rating
Strong Buy
Target Price
$17.45
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Tenaya Therapeutics, Inc. | $0.74 | — | $169.71 M | — | -70.98% | -83.84% | $2.35 / $0.36 | $0.57 |
| 2. | Aptevo Therapeutics Inc. | $5.21 | — | $6.24 M | — | -124.44% | -2.35% | $486 / $3.8 | $17.42 |
| 3. | Connect Biopharma Holdings Limited | $2.68 | — | $158.82 M | — | -24.19% | -82.72% | $3.82 / $0.65 | $0.74 |
| 4. | Axsome Therapeutics, Inc. | $184.13 | — | $9.35 B | — | -54.42% | -2.52% | $191.5 / $96.09 | $1.74 |
| 5. | REGENXBIO Inc. | $9.47 | — | $488.82 M | — | -48.13% | -1.07% | $16.19 / $5.85 | $2.02 |
| 6. | Lexicon Pharmaceuticals, Inc. | $1.84 | — | $764.74 M | — | -29.8% | -39.72% | $1.95 / $0.49 | $0.3 |
| 7. | Cocrystal Pharma, Inc. | $1.51 | — | $20.82 M | — | -120.22% | -1.11% | $2.67 / $0.86 | $0.46 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 7 M | 0 M | 0.68 M | 7.68 M | 0 M |
| Operating Profit | -60.63 M | -80.39 M | -76.85 M | -84.87 M | -84.98 M |
| Net Profit | -54.89 M | -74.15 M | -70.38 M | -77.06 M | -76 M |
| EPS in Rs | -0.31 | -0.41 | -0.39 | -0.43 | -0.43 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 15.36 M | 10.01 M | 25.55 M | 1.38 M |
| Operating Profit | -302.74 M | -385.67 M | -379.42 M | -310.95 M |
| Net Profit | -276.48 M | -337.71 M | -341.97 M | -290.51 M |
| EPS in Rs | -1.55 | -1.89 | -1.91 | -1.63 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 621.33 M | 871.3 M | 843.98 M | 1.1 B |
| Total Liabilities | 54.27 M | 93.5 M | 91.98 M | 149.55 M |
| Equity | 567.06 M | 777.79 M | 752 M | 950.22 M |
| Current Assets | 578.28 M | 809.2 M | 770.1 M | 1.02 B |
| Current Liabilities | 25.58 M | 50.73 M | 30.27 M | 63.71 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -235.46 M | -249.11 M | -300.32 M | -229.49 M |
| Investing CF | 192.8 M | -41.08 M | 257.63 M | -188.75 M |
| Financing CF | 1.6 M | 270.15 M | 34.75 M | 289.91 M |
| Free CF | -235.87 M | -251.12 M | -304.44 M | -238.55 M |
| Capex | -0.41 M | -2.02 M | -4.13 M | -9.06 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -60.83% | 1749.82% | — | — |
| Earnings Growth % | 1.25% | -17.72% | — | — |
| Profit Margin % | -3374.72% | -1338.66% | -21036.13% | — |
| Operating Margin % | -3854.04% | -1485.25% | -22516.44% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -3799.44% | -1464.62% | -22217.38% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.